Image

    Medical Management of Benign Prostatic Hyperplasia

    Eiftu Haile, Ayodeji E. Sotimehin, Bradley C. Gill
    Studysummary This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on ccjm.org →
    Discuss this study in the Community →

    Related research 4

    1. A Review on Finasteride: A 5-Alpha Reductase Inhibitor, Its Mechanism, Facts, and Benefits Journal of Drug Delivery and Therapeutics · 2019
    2. 5 Alpha-Reductase and Finasteride in Pattern Alopecia and Acne PubMed · 2004
    3. Effect of MK-386, a Novel Inhibitor of Type 1 5 Alpha-Reductase, Alone and in Combination with Finasteride, on Serum Dihydrotestosterone Concentrations in Men The Journal of Clinical Endocrinology and Metabolism · 1996
    4. Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on Serum Gonadotropins in Normal Men The Journal of Clinical Endocrinology and Metabolism · 1992